Development and validation of reversed-phase-HPLC method for simultaneous quantification of fulvestrant and disulfiram in liposomes
出版年份 2023 全文链接
标题
Development and validation of reversed-phase-HPLC method for simultaneous quantification of fulvestrant and disulfiram in liposomes
作者
关键词
-
出版物
Bioanalysis
Volume -, Issue -, Pages -
出版商
Future Science Ltd
发表日期
2023-10-17
DOI
10.4155/bio-2023-0137
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Green quality by design HPLC approach for the simultaneous determination of Bilastine and Montelukast
- (2023) Aya Roshdy et al. BMC Chemistry
- Recent advances in using liposomes for delivery of nucleic acid-based therapeutics
- (2023) Hamdi Nsairat et al. OpenNano
- PEGylated nanoassemblies composed of edelfosine and fulvestrant drugs: In vitro antiproliferative effect against breast cancer cells
- (2023) Hamdi Nsairat et al. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
- A One-Step Sample Processing Method in Combination with HPLC-MS/MS for the Simultaneous Quantification of Atorvastatin, Ezetimibe and Three Metabolites including o-Hydroxyl Atorvastatin, p-Hydroxyl Atorvastatin, and Ezetimibe-Glucuronide in Human Plasma
- (2023) T. Nguyen Nguyen Le et al. Separations
- Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies
- (2022) Ling Wang et al. Systematic Reviews
- Liposomes: structure, composition, types, and clinical applications
- (2022) Hamdi Nsairat et al. Heliyon
- Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines
- (2019) Zhi Yang et al. BIOMEDICINE & PHARMACOTHERAPY
- Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies
- (2019) Yuki Kita et al. BRITISH JOURNAL OF CANCER
- Edelfosine: an antitumor drug prototype
- (2018) Sarah Fernandes Teixeira et al. Anti-Cancer Agents in Medicinal Chemistry
- Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core–shell–corona nanoparticles
- (2018) Xiaoguang Tao et al. Biomaterials Science
- Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
- (2018) Tarah J. Ballinger et al. Frontiers in Oncology
- Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
- (2017) Changde Zhang et al. Oncotarget
- Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer
- (2016) Ji Young Kim et al. CANCER LETTERS
- Cloud point extraction of disulfiram for its HPLC-MS/MS determination in synthetic urine
- (2016) Volodymyr O. Doroschuk et al. CHEMICAL PAPERS
- FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2016) A. J. Walker et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer
- (2016) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Disulfiram chelated with copper promotes apoptosis in human breast cancer cells by impairing the mitochondria functions
- (2016) Yaping Yang et al. SCANNING
- Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations
- (2016) Hamidreza Fasehee et al. JOURNAL OF NANOBIOTECHNOLOGY
- Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08
- (2015) Khalil Zaman et al. EUROPEAN JOURNAL OF CANCER
- Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer
- (2015) Jennifer L. Allensworth et al. Molecular Oncology
- Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
- (2013) Shira Peleg Hasson et al. Breast Care
- Current trends in the use of liposomes for tumor targeting
- (2013) Pranali P Deshpande et al. Nanomedicine
- Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
- (2012) Andrea Cavazzoni et al. CANCER LETTERS
- Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry
- (2012) Jill Hochreiter et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles
- (2012) Ander Estella-Hermoso de Mendoza et al. Nanomedicine
- Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties
- (2011) N C Yip et al. BRITISH JOURNAL OF CANCER
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition
- (2009) O. K. Mirzoeva et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started